Search Results

SofPulse Inc. -- a subsidiary of Endonovo (OTC PINK: ENDV) and a proposed spin-off company -- announced today the participation of its SofPulse® Pulsed Electro-Magnetic Field (PEMF) FDA-cleared medical device in the United States Army Medical Research and Development Command (USAMRDC) May 2024 Vendor Day.

Endonovo Therapeutics Inc. is proud to announce a series of advancements in the first half of 2023.

Endonovo Therapeutics, Inc. announced its inclusion on the Federal Supply Schedule for SofPulse® Pulsed Electro Magnetic Field medical devices for distribution throughout the Federal healthcare supply channels.

Endonovo Therapeutics, Inc. (OTCQB: ENDV) US-based medical device company, today announced the full regulatory approval of its flagship product, SofPulse® by the Taiwan Food and Drug Administration (TFDA), the regulatory division of the Ministry of Health and Welfare (MOHW).

Endonovo Therapeutics, Inc. (OTCQB: ENDV) -- a medical device company known for its innovative and effective pain management solutions -- announced today that it is entering the final stages of clearance to receive a Taiwan FDA (TFDA) License for Medical Devices to distribute its flagship product, SofPulse® in Taiwan.

Endonovo Therapeutics, Inc. (OTCQB: ENDV), a medical device company specializing in pulsed electromagnetic field (PEMF) technology, announced today it will hold a question and answer session for shareholders on March 9, 2023 at 4:30pm EST with Ira Weisberg, President of Endonovo’s Medical Division.

Endonovo Therapeutics, Inc. (OTCQB: ENDV), a leading developer of medical technologies, today announced it is moving forward in its clinical development in the field of Traumatic Brain Injury (TBI) treatment.

Endonovo Therapeutics, Inc. announced a new non-exclusive stocking distributor agreement with Pulse Therapeutics Technology, Inc. to purchase and distribute its SofPulse® medical devices into Mexico and Costa Rica.

Endonovo Therapeutics, Inc. announced the retention of Ocean Tomo, a part of J.S. Held, to conduct a fairness opinion analysis in connection with the proposed spin-off of Endonovo’s medical device assets to a newly formed Delaware company, SofPulse, Inc.

Endonovo Therapeutics, Inc. (OTCQB:ENDV) today announced an agreement with NAMSA – a leading Global Contract Research Organization (CRO) and medical device reimbursement specialist – as strategic advisors to develop in-patient and out-patient medical reimbursement strategies for Endonovo’s flagship PEMF (Pulsed Electro-Magnetic Field) product SofPulse®.